We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Microfluidic Chip Captures Live Tumor Cells from Blood

By LabMedica International staff writers
Posted on 28 Aug 2013
A neoteric microfluidic chip has been developed that can quickly and efficiently segregate and capture live circulating tumor cells (CTCs) from a patient's blood.

The chip has potential applications for cancer screenings and treatment assessments as CTCs circulating within a patient's bloodstream can carry cancer from a primary tumor site to distant sites of the body, spreading the disease. More...


A team of scientists at Peking University (Beijing, China) developed the system that captures more than 90% of the CTCs, which makes it highly efficient. Overall processing time has also been shortened, due in part to a step in which red blood cells are selectively lysed, or broken apart. Lysing the red blood cells diminishes the tendency of blood to clog the system, a common problem that slows processing time in similar CTC filtering devices.

The microfluidic system consists of the chip itself, tubing, fluid connectors, syringes, and syringe pumps. Tubes and fluid connectors are used to connect the syringes, and fluidic ports punched into the microfluidic chip. The ability to count live, individual CTCs in the bloodstream can help doctors determine the severity of a cancer, since CTC density in the blood is linked to the progression of the disease and patients' likelihood of survival. The novel method could also improve "liquid biopsy" techniques, in which a small amount of blood is drawn as an alternative to conventional tissue biopsies of primary or metastatic tumors.

Ray P.S. Han, PhD, a professor and lead author, said, “Because our chip is able to capture viable CTCs, it creates opportunities for the development of new and efficient cancer biomarkers. It also gives us a chance of the grandest dream of all: a technology capable of directly removing CTCs from the human bloodstream, a form of CTC dialysis." The study was published online on June 6, 2013, in the journal Biomicrofluidics.

Related Links:
Peking University



Gold Member
Hematology Analyzer
Medonic M32B
Collection and Transport System
PurSafe Plus®
Gel Cards
DG Gel Cards
New
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.